Washington Post
“With this newer generation of medications, we’re not just focusing on weight loss,” said David Lau, an endocrinologist and professor emeritus at the University of Calgary Cumming School of Medicine. “We’re talking about changes beyond what you see on the scale.”
Novo Nordisk and Eli Lilly are both preparing to launch once-a-day weight loss pills by next year if the FDA approves them, as is widely expected. That would allow patients to avoid the jab of auto-injector pens with tiny needles.
The trade-off is that pills being tested so far don’t work as well.